# An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

> **NCT02561078** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 420 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Human regular U-500 insulin (CSII)
- **DRUG:** Human regular U-500 insulin (MDI)

## Key facts

- **NCT ID:** NCT02561078
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-20
- **Primary completion:** 2017-05-09
- **Final completion:** 2017-05-09
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2020-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561078, "An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02561078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*